Creating novel protein-based immunotherapies to treat cancer and autoimmune disorders
Alpine Immune Sciences is developing next-generation immunotherapies to treat cancer and autoimmune disorders. Alpine’s proprietary technology platforms enable the development of engineered proteins optimized to modulate multiple immune cell receptors within the immune synapse. Alpine was founded by a veteran team of biotechnology executives and scientific experts with expertise in developing recombinant protein-based immunotherapies. The company has formed a research collaboration and license agreement with Kite Pharma to incorporate Alpine’s technology into Kite’s next generation of engineered T-cell therapies.
